-
Mashup Score: 1Moderna Sues Pfizer-BioNTech Over mRNA Technology Infringement - 2 year(s) ago
The Cambridge-MA., company accuses Pfizer and BioNTech of copying patented technology in the development of their COVID-19 vaccine.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 1Pfizer-BioNTech Submits Application for EUA for Second Booster Dose of COVID-19 Vaccine - 2 year(s) ago
The application is based on 2 Israeli studies for the additional shot for people 65 years and older.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Pfizerbiontech submitted their #FDA application for the fourth #booster dose for people 65 years and older. Submission is based off 2 Israeli data sets. https://t.co/LP3uzUBsqk https://t.co/ABFA6niA9n
-
-
Mashup Score: 2In Vitro, Omicron is More Efficient at Evading Vaccine-Neutralizing Antibodies, But a Booster Increases Antibodies - 2 year(s) ago
Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI Investigators in the United Kingdom showed a #PfizerBioNTech #Booster dose increases neutralizing antibodies in a laboratory setting, and #Omicron might not be as damaging to the lungs. https://t.co/K7HlNDCyvC
-
-
Mashup Score: 1In Vitro, Omicron is More Efficient at Evading Vaccine-Neutralizing Antibodies, But a Booster Increases Antibodies - 2 year(s) ago
Investigators in the United Kingdom showed a Pfizer-BioNTech booster dose increases neutralizing antibodies in a laboratory setting, and Omicron might not be as damaging to the lungs as previous variants.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Investigators showed a #PfizerBioNTech #Booster dose increases neutralizing antibodies in a laboratory setting, and #Omicron might not be as damaging to the lungs as previous variants. https://t.co/K7HlNDkXE4
-
-
Mashup Score: 1Pfizer and BioNTech Says Lab Tests Show 3 Doses of COVID-19 Vaccine Shows Significant Protection Against Omicron - 2 year(s) ago
Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Breaking #Pfizerbiontech announce their #vaccine offers significant protection against #Omicron after 3 doses, according to preliminary lab results https://t.co/BIgALk6icV
-
-
Mashup Score: 0
In a new study, both messenger RNA vaccines available in the U.S. demonstrated high effectiveness against COVID-19, although the Moderna vaccine was associated with a lower risk for infection and hospitalization than the Pfizer-BioNTech vaccine. The trial is the “first head-to-head comparison of the effectiveness” of each vaccine, according to a press release.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
In a new #NEJM study, both messenger RNA vaccines available in the U.S. demonstrated high effectiveness against #COVID19, although the #Moderna vaccine was associated with a lower risk for infection and hospitalization than the #PfizerBioNTech vaccine https://t.co/4FWV6YNyuK
-
-
Mashup Score: 2
Pfizer-BioNTech’s request for the Emergency Use Authorization (EUA) will apply to everyone 18 years and older.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Updated: #Pfizerbiontech officially submitted their request for an #FDA EUA to administer #boostershots to all adults. https://t.co/SqGAsQZnpY
-
-
Mashup Score: 2
The emergency use authorization (EUA) is based on the vaccine data and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#Breaking #FDA approves EUA for #Pfizerbiontech #COVID19 #vaccine for children 5 to 11 years old https://t.co/jq45Pn5R28
-
-
Mashup Score: 0
This recommendation was based off of data showing the vaccine was 90% efficacious in this population, and sets the stage for the first COVID-19 vaccine in the age group.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI The #FDA VRBPAC voted to recommend the #Pfizerbiontech #COVID19 #vaccine in 5 to 11 year old children https://t.co/CSHAoayGTc
-
-
Mashup Score: 6FDA VRBPAC Meeting Today to Discuss the Pfizer-BioNTech COVID-19 Vaccine in 5 to 11 Year Olds - 3 year(s) ago
The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
News Event Reminder: #FDA VRBPAC is meeting today to discuss the #Pfizerbiontech #COVID19 #vaccine for potential EUA in the 5 to 11 year old population. Check back later today for the official news on the vote. https://t.co/UIVmZJfwcN
-
The specifics of why #Moderna is suing #PfizerBioNTech in the #mRNA patent infringement lawsuit. https://t.co/4otFQQhpx0